美國(guó)Mineralocorticoid(f-hMR) 人鹽皮質(zhì)激素受體可誘導(dǎo)表達(dá)細(xì)胞株

美國(guó)PrimCells誘導(dǎo)性穩(wěn)定細(xì)胞株： PrimCells建立的*的誘導(dǎo)性細(xì)胞高效開發(fā)系統(tǒng)，能在極短時(shí)間內(nèi)篩選出低泄漏，高誘導(dǎo)性的穩(wěn)定細(xì)胞株，成功開發(fā)出一系列核受體誘導(dǎo)表達(dá)的穩(wěn)定細(xì)胞株產(chǎn)品，為多家制藥公司研發(fā)部門和科研院所提供產(chǎn)品與服務(wù)，廣受用戶好評(píng)。針對(duì)客戶的特定需求，PrimCells亦提供量身定制服務(wù)，通過(guò)密切的客戶交流和高效的篩選體系，嚴(yán)格保證客戶在3-4周內(nèi)即獲得高質(zhì)量的誘導(dǎo)性穩(wěn)定細(xì)胞株，具有市場(chǎng)其他供應(yīng)商*的時(shí)效性。

Introduction:

Nuclear hormone receptors (NHRs) are a superfamily of transcription factors that function as powerful metabolic regulators to control a variety of systemic processes in physiology. They also play key roles in the pathophysiology of many major disease states, such as diabetes, obesity, inflammation, atherosclerosis and heart failure. To date, this superfamily has provided a rich source of drug design targets and it is continuing to be one of the hottest areas for pharmaceutical research. PrimCells now provides a comprehensive set of NHR expressing cell lines to the research community. These high-quality, flag- and/or HA-tagged NHR-expressing cell lines aim to facilitate further biochemical and molecular studies of their functions and hence encourage new strategies for drug design.

f-hMR/HEK293 cell line was created by stable co-transfection of HEK293 cells with two plasmids expressing the bacterial Tet repressor (TetR) and the human mineralocorticoid receptor (hMR) proteins. Since the hMR gene is driven by a promoter containing two tetracycline operator (TeTO2) sites, the expression of hMR protein can be induced by doxycycline.

美國(guó)Mineralocorticoid(f-hMR) 人鹽皮質(zhì)激素受體可誘導(dǎo)表達(dá)細(xì)胞株

Figure 1 | Confirmed hMR Expression in f-hMR stable cells

美國(guó)PrimCells品牌介紹

PrimCells是位于美國(guó)加州圣迭戈的一家專業(yè)致力于細(xì)胞產(chǎn)品研發(fā)和解決方案提供的業(yè)內(nèi)技術(shù)。

公司匯集了*的生物醫(yī)藥技術(shù)專家，獨(dú)立開發(fā)了多項(xiàng)原代細(xì)胞和干細(xì)胞相關(guān)的專有技術(shù)。 公司以“細(xì)胞研究的優(yōu)選擇"為宗旨，自主研發(fā)超過(guò)70種創(chuàng)新產(chǎn)品，多個(gè)特種細(xì)胞市場(chǎng)的空白。例如其誘導(dǎo)性表達(dá)細(xì)胞庫(kù)和高效3D皮膚培養(yǎng)系統(tǒng)，皆為該類產(chǎn)品目前市場(chǎng)上少數(shù)的規(guī)模化供應(yīng)商。此外，公司以高質(zhì)量的數(shù)據(jù)與快速穩(wěn)定的項(xiàng)目完成時(shí)間，長(zhǎng)期為多家制藥公司提供解決方案，獲得用戶廣泛贊譽(yù)。

PrimCells產(chǎn)品線：

• 報(bào)告基因干細(xì)胞        2. 原代細(xì)胞（含報(bào)告基因原代細(xì)胞）               3. 誘導(dǎo)性穩(wěn)定細(xì)胞株

4. 人源重組蛋白               5.   創(chuàng)新型培養(yǎng)試劑

PrimCells 解決方案

1.誘導(dǎo)性穩(wěn)定細(xì)胞株開發(fā) 2. 原代細(xì)胞開發(fā) 3. 藥物體外毒理和效能測(cè)試 4. 3D-皮膚培養(yǎng)

PrimCells合作伙伴及客戶:

A．生物制藥公司：輝瑞(Pfizer), 諾華(Novartis), 禮來(lái)(Eli2  Lilly),. Amgen, EMD Millipore, Regeneron等公司的毒理和醫(yī)藥研發(fā)部門

B．科研機(jī)構(gòu)：冷泉港實(shí)驗(yàn)室，哈佛醫(yī)學(xué)院, 麻省理工（MIT）,， UCSF, NYU, Salk, UIUC, USC等

美國(guó)Mineralocorticoid(f-hMR) 人鹽皮質(zhì)激素受體可誘導(dǎo)表達(dá)細(xì)胞株